Author Panel

Results for: cancer treatment

10 results found in 0.6 seconds
Search Sources
Database
Complete
10 results
PubMed/NCBI
Loading...
0 results
arXiv
Loading...
0 results
Semantic Scholar
Loading...
0 results
CrossRef
Loading...
0 results
2026 reyes2026identifying DATABASE
Identifying Disparities in Timely Receipt of Radiation After Breast-Conserving Surgery.

Reyes, Nicole; Ortega, Camila; Mendiola, Amanda; Murray, Mary; Fenton, Andrew; Brett-Morris, Adina; Mangira, Caroline

The breast journal , 2026 : 9942451

Radiation therapy after breast-conserving surgery reduces local recurrence and improves survival. The new standard set forth by the Commission on Cancer (CoC) requires that radiation be initiated in less than or equal to 60 days of definitive surgery for patients receiving breast-conserving surgery for Stages I-III breast cancer who do not undergo adjuvant chemo or immunotherapy. Timely access to radiation is critical, and yet there still exists a modest number of patients who experience delays in the initiation of radiation. We aim to highlight this disparity at our institution and identify the socioeconomic factors that contribute to it. Using the Breast Cancer Registry, we conducted a retrospective analysis of women diagnosed with Stages I-III breast cancer, who underwent breast-conserving surgery between 2011 and 2021. Women who received chemotherapy were excluded. We stratified patients based on socioeconomic and other factors and examined which factors attributed to an increased interval from surgery to initiation of radiation greater than the current standard of 60 days. A cohort of 427 women meeting the inclusion criteria was identified. Most patients received adjuvant radiation within the new standard of 60 days from definitive surgery (72.4%). However, patients of White race were significantly more likely to receive adjuvant radiation within 60 days of final surgery (74.7%) compared to patients of Black race (55.6%). In addition, patients with private insurance or Medicare were more likely to receive adjuvant radiation within the current set standard (74.9% and 74.5%, respectively) in comparison to patients with Medicaid (50.0%). This analysis identifies disparities in breast cancer treatment among minority populations at our institution. It also suggests that insurance status can affect the receipt of treatment in a recommended time frame. There is research that shows a delay in radiation impairs survival. These results indicate that improving access to timely adjuvant radiation may be leveraged to lessen disparities experienced by minority races regardless of insurance status.
2026 villemure-poliquin2026head DATABASE
Head and Neck Cancers Medical Costs in a Universal Health System: A Population-Based Case-Control Study.

Villemure-Poliquin, Noémie; Fu, Rui; Chan, Kelvin K W; Li, Qing; Ayoo, Kennedy; Wright, Frances; Karam, Irene; Coburn, Natalie G; Hallet, Julie; Eskander, Antoine

Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale , 55 : 19160216251406521

ImportanceHead and neck cancers (HNC) impose a significant economic burden on healthcare systems. Understanding the direct medical costs across different phases of care is crucial for resource allocation and cost-effectiveness evaluations, particularly in universal healthcare settings.ObjectiveTo quantify the direct medical costs of HNC over 60 months postdiagnosis and examine cost variations by cancer subsite, stage, and treatment modality.DesignPopulation-based, matched case-control study using administrative healthcare data.SettingOntario, Canada, a province with a publicly funded universal healthcare system.ParticipantsWe included 19,832 adults diagnosed with HNC between 2007 and 2020. Each case was matched with 5 noncancer controls based on age, sex, and comorbidity.ExposuresHNC diagnosis, categorized by cancer subsite, stage, and treatment modality.Main Outcome MeasuresMean per-person direct medical costs attributable to HNC over a 63-month period, analyzed by phase of care, cancer subsite, stage, and treatment modality.ResultsThe mean per-person cost attributable to HNC over 63 months was $53,812.9 ± $762.2. Costs peaked in the first 3 months postdiagnosis ($9709.7 ± $36.1 per month) and declined over time. Larynx/hypopharynx cancers incurred the highest costs across most phases. Advanced-stage cancers were associated with increased costs, with stage IV cancers nearly doubling the costs of stage I. Multimodal treatments, particularly surgery combined with chemoradiation, resulted in the highest costs across all phases ( < .01).ConclusionsHNC results in substantial healthcare costs, with significant variations by subsite, stage, and treatment modality. The highest costs occur in the early treatment phase and remain elevated for patients requiring multimodal therapies.RelevanceThese findings provide critical data for policymakers and health system authorities to optimize resource allocation and assess cost-effectiveness. Future research should explore indirect costs and the impact of early detection strategies to reduce the economic burden of HNC.Level of evidence3.
2026 xu2026ftomediated DATABASE
FTO-mediated m6A demethylation of CSF3 suppresses NETosis via downregulation of RLN2 expression in colorectal cancer.

Xu, Junfeng; Zhang, Jie; Li, Ruoran; Chen, Shengxin; Duan, Changwei; Ma, Xianzong; Wang, Xuexin; Liu, Xinyan; Gu, Lingyun; Meng, Ke; Li, Mingyang

Cell biology and toxicology , 42 : 4

CSF3 exerts a significant function in the progression of colorectal cancer (CRC). N6-methyladenosine (m6A) modification is now considered the main driving factor of RNA influence for maintaining homeostasis in cancer cells. Nevertheless, how m6A mediates the role of CSF3 and its influence in pathogenesis of CRC is still elusive. After neutrophil isolation from bone marrow, the purity and survival rate of neutrophils were assessed. Azoxymethane (AOM)/Dextran Sodium Sulfate (DSS) was employed to construct the CRC mice model. Both loss-of-function and gain-of-function experiments were conducted to explore the influence of CSF3 on NETosis and tumorigenesis of CRC in vitro and in vivo. The purity and survival rate of neutrophils were 88.07% and 94.84%, respectively. Overexpression of CSF3 (oe-CSF3) markedly enhanced NETosis, while CSF3 knockdown (sh-CSF3) suppressed it. Intriguingly, CSF3 expression positively correlated with relaxin-2 (RLN2) levels in CRC cells, and RLN2 supplementation rescued tumorigenesis and NETosis after sh-CSF3 treatment. Mechanistically, fat mass and obesity-associated protein (FTO)-mediated m6A demethylation of CSF3 mRNA suppressed CRC tumorigenesis in vivo. CSF3 upregulation counteracted the tumor-suppressive effects of FTO overexpression, restoring NETosis and tumor growth. Consistent with this, FTO overexpression in CRC mice alleviated disease severity, as evidenced by improved body weight, reduced tumor burden, and diminished NETosis. Collectively, our findings establish a novel regulatory axis in which FTO-dependent m6A demethylation of CSF3 suppresses NETosis by inhibiting RLN2 expression, offering new insights into therapeutic targeting of the m6A-CSF3-RLN2 pathway in CRC.
2025 2025the DATABASE
The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023.

Lancet (London, England) , 406 : 1565-1586

Cancer is a leading cause of death globally. Accurate cancer burden information is crucial for policy planning, but many countries do not have up-to-date cancer surveillance data. To inform global cancer-control efforts, we used the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 framework to generate and analyse estimates of cancer burden for 47 cancer types or groupings by age, sex, and 204 countries and territories from 1990 to 2023, cancer burden attributable to selected risk factors from 1990 to 2023, and forecasted cancer burden up to 2050. Cancer estimation in GBD 2023 used data from population-based cancer registration systems, vital registration systems, and verbal autopsies. Cancer mortality was estimated using ensemble models, with incidence informed by mortality estimates and mortality-to-incidence ratios (MIRs). Prevalence estimates were generated from modelled survival estimates, then multiplied by disability weights to estimate years lived with disability (YLDs). Years of life lost (YLLs) were estimated by multiplying age-specific cancer deaths by the GBD standard life expectancy at the age of death. Disability-adjusted life-years (DALYs) were calculated as the sum of YLLs and YLDs. We used the GBD 2023 comparative risk assessment framework to estimate cancer burden attributable to 44 behavioural, environmental and occupational, and metabolic risk factors. To forecast cancer burden from 2024 to 2050, we used the GBD 2023 forecasting framework, which included forecasts of relevant risk factor exposures and used Socio-demographic Index as a covariate for forecasting the proportion of each cancer not affected by these risk factors. Progress towards the UN Sustainable Development Goal (SDG) target 3.4 aim to reduce non-communicable disease mortality by a third between 2015 and 2030 was estimated for cancer. In 2023, excluding non-melanoma skin cancers, there were 18·5 million (95% uncertainty interval 16·4 to 20·7) incident cases of cancer and 10·4 million (9·65 to 10·9) deaths, contributing to 271 million (255 to 285) DALYs globally. Of these, 57·9% (56·1 to 59·8) of incident cases and 65·8% (64·3 to 67·6) of cancer deaths occurred in low-income to upper-middle-income countries based on World Bank income group classifications. Cancer was the second leading cause of deaths globally in 2023 after cardiovascular diseases. There were 4·33 million (3·85 to 4·78) risk-attributable cancer deaths globally in 2023, comprising 41·7% (37·8 to 45·4) of all cancer deaths. Risk-attributable cancer deaths increased by 72·3% (57·1 to 86·8) from 1990 to 2023, whereas overall global cancer deaths increased by 74·3% (62·2 to 86·2) over the same period. The reference forecasts (the most likely future) estimate that in 2050 there will be 30·5 million (22·9 to 38·9) cases and 18·6 million (15·6 to 21·5) deaths from cancer globally, 60·7% (41·9 to 80·6) and 74·5% (50·1 to 104·2) increases from 2024, respectively. These forecasted increases in deaths are greater in low-income and middle-income countries (90·6% [61·0 to 127·0]) compared with high-income countries (42·8% [28·3 to 58·6]). Most of these increases are likely due to demographic changes, as age-standardised death rates are forecast to change by -5·6% (-12·8 to 4·6) between 2024 and 2050 globally. Between 2015 and 2030, the probability of dying due to cancer between the ages of 30 years and 70 years was forecasted to have a relative decrease of 6·5% (3·2 to 10·3). Cancer is a major contributor to global disease burden, with increasing numbers of cases and deaths forecasted up to 2050 and a disproportionate growth in burden in countries with scarce resources. The decline in age-standardised mortality rates from cancer is encouraging but insufficient to meet the SDG target set for 2030. Effectively and sustainably addressing cancer burden globally will require comprehensive national and international efforts that consider health systems and context in the development and implementation of cancer-control strategies across the continuum of prevention, diagnosis, and treatment. Gates Foundation, St Jude Children's Research Hospital, and St Baldrick's Foundation.
2025 ros2025surrogate DATABASE
Surrogate to predict overall survival in patients with V600E-mutant colorectal cancer treated with BRAF inhibitor combinations.

Ros, J; Navarro, V; Villacampa, G; Baraibar, I; Salvà, F; Rodriguez, M; Vaghi, C; Garcia, A; Alcaraz, A; Tabernero, J; Élez, E; Dienstmann, R

ESMO gastrointestinal oncology , 9 : 100225

The V600E mutation, found in up to 12% of patients with metastatic colorectal cancer, is associated with aggressive disease and poor response to standard chemotherapy. However, the advent of BRAF inhibitors has led to improved clinical outcomes and survival. While surrogate endpoints for predicting overall survival (OS) have been extensively studied in the overall colorectal cancer population treated with chemotherapy, their applicability in patients with V600E-mutant colorectal cancer receiving either BRAF inhibitor combinations or conventional chemotherapy remains unclear, and needs to be better elucidated. The aim of the study was to evaluate surrogate endpoints to predict OS in patients with V600E-mutant colorectal cancer treated with either BRAF inhibitor combinations or chemotherapy. A systematic review was carried out to identify clinical trials or real-world cohorts evaluating patients with -mutant colorectal cancer treated either with chemotherapy or BRAF inhibitor combinations. A control cohort of melanoma patients treated with BRAF inhibitors in a phase III randomized trial was included. Adjusted ( ) values were calculated to quantify the association between surrogate endpoints and median OS. Overall, a total of 5227 patients included in 29 cohorts were analyzed. Among patients with colorectal cancer treated with chemotherapy, overall response rate (ORR) and disease control rate (DCR) showed a high correlation with OS ( > 0.90). Among patients treated with targeted therapy, progression-free survival (PFS) showed the highest correlation with OS ( = 0.90). In the melanoma cohort, PFS was strongly associated with OS ( = 0.92). In -mutant colorectal cancer, standard surrogate endpoints for chemotherapy-based treatments accurately predict OS; however, when patients are treated with targeted therapies, both ORR and PFS have proven to be reliable predictors of survival.
2025 salvà2025retreatment DATABASE
Retreatment with oxaliplatin-based regimens in refractory metastatic colorectal cancer: characterization of high-response patients.

Salvà, F; Catani, G; Saoudi, N; Baraibar, I; Ros, J; Rodriguez, M; Salvà de Torres, C; Alcaraz, A; Garcia, A; Comas, R; Ruiz-Pace, F; Rezqallah, A; Dienstmann, R; Tabernero, J; Elez, E

ESMO gastrointestinal oncology , 9 : 100230

Oxaliplatin, a key agent used for managing metastatic colorectal cancer (mCRC), is often discontinued due to cumulative toxicity. Its reintroduction in later treatment lines remains a common clinical practice, despite the absence of robust prospective trials supporting this therapeutic strategy. This study aimed to evaluate the efficacy of oxaliplatin rechallenge in refractory mCRC and to identify patient characteristics predictive of improved outcomes with this approach. We retrospectively analyzed patients treated with oxaliplatin in the third- or fourth-line setting at Vall d'Hebron Hospital between 2015 and 2021. Outcomes included overall response rate (ORR), disease control rate (DCR), and median progression-free survival (PFS). Patients achieving median PFS >6 months were classified as best-responders. Factors affecting PFS were analyzed with a Cox regression model. Amplicon-seq analysis of 61 genes was carried out using Illumina technology. Of 735 patients receiving third- or fourth-line treatment, 102 (14%) received oxaliplatin retreatment (69% in third line; 31% in fourth line). Median PFS was 4.0 months (95% CI 3.29-5.03 months), with an ORR of 12% and DCR of 39%. Twenty-eight patients (27%) were best-responders. Predictors of efficacy included response to first-line oxaliplatin, planned oxaliplatin discontinuation, and an oxaliplatin-free interval of at least 22.0 months. No significant associations were identified between molecular alterations and prognostic subgroups. Oxaliplatin-based reintroduction therapy is a viable strategy in mCRC, particularly for patients with a favorable prior response and prolonged oxaliplatin-free intervals. However, identifying more precise biomarkers is essential to improve patient selection and maximize treatment efficacy.
2024 reid2024the DATABASE
The every woman study™ low- and middle-income countries edition protocol: A multi-country observational study to assess opportunities and challenges to improving survival and quality of life for women with ovarian cancer.

Reid, Frances; Adams, Tracey; Adel, Rafe Sadnan; Andrade, Carlos E; Bajwa, Anmol; Bambury, Ian G; Benhima, Nada; Bolatbekova, Raikhan; Leon, David Cantu-De; Charlton, Phaedra; Chirinos, Carlos Chávez; Cohen, Robin; Eiken, Mary; Estrada, Erick Estuardo; Kaidarova, Dilyara; Lau, Iren; MacKay, Clara; Makondi, Precious Takondwa; Mukhopadhyay, Asima; Mustapha, Aisha; Noll, Florencia; Origa, Martin; Pariyar, Jitendra; Pervin, Shahana; Phan, Ngoc T H; Refky, Basel; Shaffi, Afrin F; Strömsholm, Eva-Maria; Woo, Yin Ling; Yoon, Sook-Yee; Zakirova, Nargiza; Chidebe, Runcie C W; Funston, Garth; Soerjomataram, Isabelle

PLoS ONE , 19 : e0298154

Ovarian cancer is a challenging disease to diagnose and treat effectively with five-year survival rates below 50%. Previous patient experience research in high-income countries highlighted common challenges and opportunities to improve survival and quality of life for women affected by ovarian cancer. However, no comparable data exist for low-and middle-income countries, where 70% of women with the disease live. This study aims to address this evidence gap. This is an observational multi-country study set in low- and middle-income countries. We aim to recruit over 2000 women diagnosed with ovarian cancer across multiple hospitals in 24 countries in Asia, Africa and South America. Country sample sizes have been calculated (n = 70-96 participants /country), taking account of varying national five-year disease prevalence rates. Women within five years of their diagnosis, who are in contact with participating hospitals, are invited to take part in the study. A questionnaire has been adapted from a tool previously used in high-income countries. It comprises 57 multiple choice and two open-ended questions designed to collect information on demographics, women's knowledge of ovarian cancer, route to diagnosis, access to treatments, surgery and genetic testing, support needs, the impact of the disease on women and their families, and their priorities for action. The questionnaire has been designed in English, translated into local languages and tested according to local ethics requirements. Questionnaires will be administered by a trained member of the clinical team. This study will inform further research, advocacy, and action in low- and middle-income countries based on tailored approaches to the national, regional and global challenges and opportunities. In addition, participating countries can choose to repeat the study to track progress and the protocol can be adapted for other countries and other diseases.
2023 chavda2023advanced DATABASE
Advanced Phytochemical-Based Nanocarrier Systems for the Treatment of Breast Cancer

Vivek P. Chavda; Lakshmi Vineela Nalla; Pankti C. Balar; Rajashri Bezbaruah; V. Apostolopoulos; Rajeev K. Singla; A. Khadela; Lalitkumar K. Vora; V. Uversky

Cancers

Simple Summary Breast cancer is a concern for the healthcare system. Even with the advancement of science and technology, the current system for therapeutics and diagnostics seems to have numerous pitfalls. Phytochemical-mediated nanocarriers come into the picture to outrange the drawbacks of the conventional breast cancer management method. Phytochemicals have been a useful tool since time immemorial, and developing a sophisticated fusion of these chemicals with nanocarrier enhanced its effectiveness. This ensures targeted, time-controlled drug delivery. This article emphasizes the development of phytochemical-based nanocarriers corresponding to breast cancer. Moreover, the article presents the unhighlighted parts of the therapeutical industry to help patients. Enhancing patients’ quality of life would uplift the healthcare system. Abstract As the world’s most prevalent cancer, breast cancer imposes a significant societal health burden and is among the leading causes of cancer death in women worldwide. Despite the notable improvements in survival in countries with early detection programs, combined with different modes of treatment to eradicate invasive disease, the current chemotherapy regimen faces significant challenges associated with chemotherapy-induced side effects and the development of drug resistance. Therefore, serious concerns regarding current chemotherapeutics are pressuring researchers to develop alternative therapeutics with better efficacy and safety. Due to their extremely biocompatible nature and efficient destruction of cancer cells via numerous mechanisms, phytochemicals have emerged as one of the attractive alternative therapies for chemotherapeutics to treat breast cancer. Additionally, phytofabricated nanocarriers, whether used alone or in conjunction with other loaded phytotherapeutics or chemotherapeutics, showed promising results in treating breast cancer. In the current review, we emphasize the anticancer activity of phytochemical-instigated nanocarriers and phytochemical-loaded nanocarriers against breast cancer both in vitro and in vivo. Since diverse mechanisms are implicated in the anticancer activity of phytochemicals, a strong emphasis is placed on the anticancer pathways underlying their action. Furthermore, we discuss the selective targeted delivery of phytofabricated nanocarriers to cancer cells and consider research gaps, recent developments, and the druggability of phytoceuticals. Combining phytochemical and chemotherapeutic agents with nanotechnology might have far-reaching impacts in the future.
2023 herrera-calderon2023 DATABASE
Jacq. induces cytotoxicity, antiproliferative activity, and cell death in colorectal cancer cells via regulation of caspase 3 and p53.

Herrera-Calderon, Oscar; Herrera-Ramírez, Angie; Cardona-G, Wilson; Melgar-Merino, Elizabeth Julia; Chávez, Haydee; Pari-Olarte, Josefa Bertha; Loyola-Gonzales, Eddie; Kong-Chirinos, José Francisco; Almeida-Galindo, José Santiago; Peña-Rojas, Gilmar; Andía-Ayme, Vidalina

Frontiers in Pharmacology , 14 : 1197569

Colorectal cancer (CRC) is the third most common cancer diagnosed worldwide and is the second leading cause of cancer-related death due to an insufficiency prognosis and is generally diagnosed in the last step of development. The Peruvian flora has a wide variety of medicinal plants with therapeutic potential in several diseases. Jacq. is a plant used to treat inflammatory process as well as gastrointestinal diseases. The aim of this study was to examine the cytotoxic, antiproliferative, and cell death-inducing effects of on colorectal cancer cells (SW480 and SW620). The hydroethanolic extract was obtained by maceration at 70% ethanol, the phytochemical constituents were identified by LC-ESI-MS. revealed 57 compounds some of them are: isorhamnetin, kaempferol, quercetin, methyl dodovisate B, hardwickiic acid, viscosol, and dodonic acid. Regarding the antitumoral activity, induced cytotoxic and antiproliferative activity in both SW480 and SW620 cancer cells, accompanied with, important changes in mitochondrial membrane potential, formation of the Sub G0/G1 population and increasing levels of apoptotic biomarkers (caspase 3 and the tumor suppressor protein p53) in the metastatic derivative cell line (SW620), suggesting an intrinsic apoptotic process after the treatment with the hydroethanolic extract of .
2016 catalano2016role DATABASE
Role of phytochemicals in the chemoprevention of tumors

Enrico Catalano

arXiv Preprint

Phytochemicals are plant-derived secondary metabolites, which may exert many biological activities in humans, including anticancer properties. Although recent findings appear to support their role in cancer prevention and treatment, this issue is still controversial. Anti-cancer activity of phytochemicals mainly depends on their multi-target mechanism of action, including antimutagenic, antioxidant and antiproliferative activities. Furthermore, they may modulate the host immune response to cancer, reducing inflammatory microenvironment and enhancing lymphocyte onco-surveillance. Since carcinogenesis is multi-factorial and involves several signaling pathways, multi-targeted agents as phytochemicals may represent promising anticancer compounds. This narrative review aims to analyze the current literature on phytochemicals highlighting their specific targets on carcinogenic molecular pathways and their chemopreventive role. A full comprehension of their activity at molecular and cellular levels will contribute for a better understanding of phytochemical clinical efficacy, thus promoting the identification of new effective plant-derived therapeutics.